SEC Form 8-K Summary
Registrant: Vallon Pharmaceuticals, Inc. The request metadata identifies GRI Bio, Inc., but the filing itself names Vallon Pharmaceuticals, Inc. as the registrant.
Report date: December 28, 2022; signed December 29, 2022. The filing addresses Nasdaq listing compliance and does not report operating or financial results for a reporting period.
Business Context and Key Financial Metrics
- The company’s common stock traded on The Nasdaq Capital Market under the symbol VLON.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics.
- Nasdaq determined that the company had not regained compliance with the $1.00 minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
- The company also did not meet the $5.0 million stockholders’ equity requirement for eligibility for a second 180-day compliance period.
Material Developments
- On June 27, 2022, Nasdaq notified the company that its stock had traded below $1.00 per share for 30 consecutive business days and granted an initial 180-day compliance period ending December 27, 2022.
- On December 28, 2022, Nasdaq notified the company that its shares would be scheduled for suspension at the opening of business on January 6, 2023, followed by delisting, unless the company timely requested a hearing.
- The company intended to request a hearing before a Nasdaq Hearings Panel. The request would stay the suspension and delisting action pending the hearing and any extension granted by the Panel.
- On December 23, 2022, the company filed a preliminary proxy statement/prospectus/information statement on Form S-4 regarding a proposed reverse stock split.
- If approved by stockholders and implemented by the board through an amendment to the certificate of incorporation, the reverse stock split could help the company regain compliance with the minimum bid price requirement.
Outlook, Risks, and Contingencies
- There is no assurance that the Nasdaq Hearings Panel will grant an extension or that the company will satisfy all continued-listing requirements.
- There is no assurance that the reverse stock split will be approved, implemented, or completed before a suspension or delisting.
- If suspended, the common stock would cease to be quoted on The Nasdaq Capital Market.
- The company identified potential costs and management distraction associated with the Nasdaq proceedings and compliance efforts.
- The filing’s forward-looking statements are subject to risks disclosed in the company’s periodic SEC filings.
Investor Verification Items
- Verify the outcome of the Nasdaq hearing and whether any compliance extension was granted.
- Verify whether the company’s stock was suspended or delisted on or after January 6, 2023.
- Verify stockholder approval and implementation of the proposed reverse stock split.
- Review subsequent SEC filings for the company’s stockholders’ equity, liquidity, financing needs, and any additional Nasdaq deficiencies.
- Confirm the correct issuer identity, because the supplied metadata names GRI Bio, Inc., while this filing names Vallon Pharmaceuticals, Inc.